Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang
{"title":"依拉瓦环素治疗肺移植受者耐碳青霉烯鲍曼不动杆菌:一项真实世界回顾性研究。","authors":"Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang","doi":"10.2147/IDR.S529016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.</p><p><strong>Methods: </strong>This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.</p><p><strong>Results: </strong>A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.</p><p><strong>Conclusion: </strong>This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"4125-4139"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367918/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eravacycline Treatment for Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Lung Transplant Recipients: A Real-World Retrospective Study.\",\"authors\":\"Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang\",\"doi\":\"10.2147/IDR.S529016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.</p><p><strong>Methods: </strong>This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.</p><p><strong>Results: </strong>A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.</p><p><strong>Conclusion: </strong>This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.</p>\",\"PeriodicalId\":13577,\"journal\":{\"name\":\"Infection and Drug Resistance\",\"volume\":\"18 \",\"pages\":\"4125-4139\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367918/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Drug Resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IDR.S529016\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S529016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Eravacycline Treatment for Carbapenem-Resistant Acinetobacter baumannii in Lung Transplant Recipients: A Real-World Retrospective Study.
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.
Methods: This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.
Results: A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.
Conclusion: This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.
期刊介绍:
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.